metastatic colorectal cancer (mCRC)

Two CE-marked IVD liquid biopsy tests have been launched by molecular diagnostics company, Biocartis Group. — the Idylla ctKRAS Mutation Test and the Idylla ctNRAS-BRAF Mutation Test. more


Merck, Array BioPharma and Pierre Fabre have initiated a prospective, randomised, global phase three clinical trial for a treatment of BRAF-mutant metastatic colorectal cancer (mCRC) more


Biocartis has signed a collaboration agreement with Merck for the development and commercialisation of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC) more